[size= 14px]The anti-HRV monoclonal antibody specifically targets human rhinovirus, the primary cause of the common cold. By binding to viral capsid proteins, it helps neutralize the virus and block infection. This antibody shows potential in therapeutic applications for immunocompromised patients, reducing the severity and duration of HRV-induced respiratory symptoms in vulnerable populations.[/size]